CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
CERo Therapeutics (NASDAQ:CERO) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111, providing composition of matter and method of use protection for CER-1236 through 2041. The patent will offer comprehensive protection for their cancer treatment compound.
The company also secured a patent in Japan for its CER platform, bringing their total intellectual property portfolio to 18 patents and 2 allowed applications internationally. This strengthens CERo's position, complementing their recent FDA Fast Track and Orphan Drug Designations, while they continue to progress with their Phase 1 clinical trial.
CERo Therapeutics (NASDAQ:CERO) ha ricevuto un Notice of Allowance dall'Ufficio brevetti e marchi statunitense per la domanda 19/019,111, garantendo la protezione della composizione e dell'uso terapeutico di CER-1236 fino al 2041. Il brevetto offrir脿 una protezione completa per il loro composto anticancro.
La societ脿 ha inoltre ottenuto un brevetto in Giappone per la sua piattaforma CER, portando il portafoglio di propriet脿 intellettuale a 18 brevetti e 2 domande concesse a livello internazionale. Ci貌 rafforza la posizione di CERo, integrando le recenti designazioni FDA Fast Track e Orphan Drug, mentre proseguono con la loro fase 1 di sperimentazione clinica.
CERo Therapeutics (NASDAQ:CERO) ha recibido un Notice of Allowance de la Oficina de Patentes y Marcas de EE. UU. para su solicitud 19/019,111, proporcionando protecci贸n de composici贸n y m茅todo de uso para CER-1236 hasta 2041. La patente brindar谩 una protecci贸n integral para su compuesto contra el c谩ncer.
La compa帽铆a tambi茅n asegur贸 una patente en Jap贸n para su plataforma CER, elevando su cartera de propiedad intelectual a 18 patentes y 2 solicitudes aprobadas a nivel internacional. Esto fortalece la posici贸n de CERo, complementando sus recientes designaciones FDA Fast Track y Orphan Drug, mientras avanzan con su ensayo cl铆nico de fase 1.
CERo Therapeutics (NASDAQ:CERO)電� 氙戈淡 韸鬼棃觳�(USPTO)鞙茧攵�韯� 於滌洂氩堩樃 19/019,111鞐� 雽�頃� Notice of Allowance毳� 氚涭晿鞙茧┌, 鞚措鞃� CER-1236鞚� 氍检 甑劚 氚� 靷毄 氚╇矔鞐� 雽�頃� 2041雲勱箤歆� 氤错樃毳� 氚涥矊 霅╇媹雼�. 頃措嫻 韸鬼棃電� 頃晹鞝� 頉勲炒氍检鞐� 雽�頃� 韽磩鞝� 氤错樃毳� 鞝滉车頃╇媹雼�.
須岇偓電� 霕愴暅 鞛愳偓 CER 頂岆灚韽检棎 雽�頃� 鞚茧掣鞐愳劀 韸鬼棃毳� 頇曤炒頃橃棳 甑牅鞝侅溂搿� 齑� 18瓯挫潣 韸鬼棃鞕� 2瓯挫潣 項堦皜霅� 於滌洂鞚� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞚措姅 斓滉芳 FDA鞚� 韺姢韸疙姼霝� 氚� 頋穩鞚橃暯頀�(Orphan Drug) 歆�鞝曣臣 頃粯 CERo鞚� 鞛呾毳� 臧曧檾頃橂┌, 1靸� 鞛勳儊鞁滍棙鞚� 瓿勳啀 歆勴枆頃橂姅 雿� 霃勳泙鞚� 霅╇媹雼�.
CERo Therapeutics (NASDAQ:CERO) a re莽u un Notice of Allowance de l'Office am茅ricain des brevets et des marques pour sa demande 19/019,111, offrant une protection de composition et d'utilisation pour CER-1236 jusqu'en 2041. Le brevet assurera une protection compl猫te pour leur compos茅 anticanc茅reux.
La soci茅t茅 a 茅galement obtenu un brevet au Japon pour sa plateforme CER, portant son portefeuille de propri茅t茅 intellectuelle 脿 18 brevets et 2 demandes accept茅es au niveau international. Cela renforce la position de CERo, compl茅tant ses r茅centes d茅signations FDA Fast Track et Orphan Drug, tandis qu'elle poursuit sa phase 1 d'essai clinique.
CERo Therapeutics (NASDAQ:CERO) hat vom US-Patent- und Markenamt f眉r die Anmeldung 19/019,111 eine Notice of Allowance erhalten, die Schutz f眉r die Stoffzusammensetzung und die Anwendungsweise von CER-1236 bis 2041 gew盲hrt. Das Patent bietet umfassenden Schutz f眉r ihren krebsbek盲mpfenden Wirkstoff.
Das Unternehmen sicherte sich au脽erdem ein Patent in Japan f眉r seine CER-Plattform und bringt damit sein internationales geistiges Eigentum auf insgesamt 18 Patente und 2 zugelassene Anmeldungen. Dies st盲rkt CERos Position und erg盲nzt die j眉ngsten FDA Fast Track- und Orphan-Drug-Designationen, w盲hrend das Unternehmen mit der Phase-1-Studie 蹿辞谤迟蹿盲丑谤迟.
- Patent protection for CER-1236 secured until 2041 in the US
- Expanded patent portfolio to 20 total patents/applications internationally
- Recent FDA Fast Track and Orphan Drug Designations strengthen market position
- Ongoing progress in Phase 1 clinical trial development
- None.
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology
SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (鈥淐ERo鈥� or the 鈥淐ompany鈥�) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, 聽announces the Company received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111.聽 The patent that will issue will provide the Company with both composition of matter protection for CER-1236 and protection for the use of CER-1236 to treat cancer, through 2041. Upon issuance, this patent will provide the most comprehensive protection specific to CER-1236 to date.聽
The Company also obtained a patent in Japan, which provides protection for the CER platform.The newly allowed U.S. application and issued Japanese patent join 17 other patents and another allowed application, bringing the total to 18 patents and 2 allowed applications covering CER-1236 and its platform technology internationally.聽
鈥淥ur intellectual property portfolio is stronger than ever, with our lead compound now receiving the Notice of Allowance in the United States. Combined with our recent announcements of Fast Track and Orphan Drug Designations from the FDA, we are in a strong regulatory position with regard to exclusivity. We are also continuing to make important progress in our ongoing Phase 1 clinical trial and look forward to continued updates on all developments,鈥� said CERo Therapeutics CEO Chris Ehrlich.聽
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body鈥檚 full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (鈥淐ER-T鈥�). CERo believes the differentiated activity of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渟trive,鈥� 鈥渨ould鈥� and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo鈥檚 management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo鈥檚 filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo鈥檚 filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
Investors:
CORE IR
FAQ
What patent protection did CERo Therapeutics (CERO) receive for CER-1236?
How many patents does CERo Therapeutics now have in total?
What FDA designations has CERo Therapeutics received for CER-1236?
What stage of clinical development is CER-1236 currently in?
What type of protection did CERo receive in Japan?
